BRIEF-Molecular Templates Approved Liquidation & Wind Up Through A Dissolution

Reuters

12 Oct 2024

Molecular Templates Inc :

* MOLECULAR TEMPLATES: APPROVED LIQUIDATION & WIND UP THROUGH A DISSOLUTION

* MOLECULAR TEMPLATES: CONTINUING TO PURSUE STRATEGIC ALTERNATIVES AND POTENTIAL FUNDING SOURCES

* MOLECULAR TEMPLATES: INTENDS TO CALL SPECIAL MEETING OF STOCKHOLDERS TO SEEK APPROVAL OF PLAN OF DISTRIBUTION

* MOLECULAR TEMPLATES: PLANS TO WIND DOWN PHASE 1 CLINICAL STUDIES FOR MT-6402 AND MT-8421

* MOLECULAR TEMPLATES: TO CONTINUE DISCUSSIONS WITH FDA WITH RESPECT TO MT-0169 FOR AUTOIMMUNE INDICATIONS

* MOLECULAR TEMPLATES INC: APPROVED A REDUCTION IN FORCE OF SUBSTANTIALLY ALL OF COMPANY'S EMPLOYEES

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2474067023"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2474067023\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2474067023?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-12 05:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474067023","market":"us","top_or_hot":-1,"title":"BRIEF-Molecular Templates Approved Liquidation & Wind Up Through A Dissolution","media":"Reuters","content":"<html><body><p>Molecular Templates Inc   :</p><p>   * MOLECULAR TEMPLATES: APPROVED LIQUIDATION &amp; WIND UP THROUGH A DISSOLUTION</p><p>   * MOLECULAR TEMPLATES: CONTINUING TO PURSUE STRATEGIC ALTERNATIVES AND POTENTIAL FUNDING SOURCES</p><p>   * MOLECULAR TEMPLATES: INTENDS TO CALL SPECIAL MEETING OF STOCKHOLDERS TO SEEK APPROVAL OF PLAN OF DISTRIBUTION</p><p>   * MOLECULAR TEMPLATES: PLANS TO WIND DOWN PHASE 1 CLINICAL STUDIES FOR MT-6402 AND MT-8421</p><p>   * MOLECULAR TEMPLATES: TO CONTINUE DISCUSSIONS WITH FDA WITH RESPECT TO MT-0169 FOR AUTOIMMUNE INDICATIONS</p><p>   * MOLECULAR TEMPLATES INC: APPROVED A REDUCTION IN FORCE OF SUBSTANTIALLY ALL OF COMPANY'S EMPLOYEES</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Molecular Templates Approved Liquidation & Wind Up Through A Dissolution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Molecular Templates Approved Liquidation & Wind Up Through A Dissolution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-12 05:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Molecular Templates Inc   :</p><p>   * MOLECULAR TEMPLATES: APPROVED LIQUIDATION &amp; WIND UP THROUGH A DISSOLUTION</p><p>   * MOLECULAR TEMPLATES: CONTINUING TO PURSUE STRATEGIC ALTERNATIVES AND POTENTIAL FUNDING SOURCES</p><p>   * MOLECULAR TEMPLATES: INTENDS TO CALL SPECIAL MEETING OF STOCKHOLDERS TO SEEK APPROVAL OF PLAN OF DISTRIBUTION</p><p>   * MOLECULAR TEMPLATES: PLANS TO WIND DOWN PHASE 1 CLINICAL STUDIES FOR MT-6402 AND MT-8421</p><p>   * MOLECULAR TEMPLATES: TO CONTINUE DISCUSSIONS WITH FDA WITH RESPECT TO MT-0169 FOR AUTOIMMUNE INDICATIONS</p><p>   * MOLECULAR TEMPLATES INC: APPROVED A REDUCTION IN FORCE OF SUBSTANTIALLY ALL OF COMPANY'S EMPLOYEES</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2474067023","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474067023","pubTimestamp":1728683031,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Molecular Templates Inc   :   * MOLECULAR TEMPLATES: APPROVED LIQUIDATION & WIND UP THROUGH A DISSOLUTION   * MOLECULAR TEMPLATES: CONTINUING TO PURSUE STRATEGIC ALTERNATIVES AND POTENTIAL FUNDING SOURCES   * MOLECULAR TEMPLATES: INTENDS TO CALL SPECIAL MEETING OF STOCKHOLDERS TO SEEK APPROVAL OF PLAN OF DISTRIBUTION   * MOLECULAR TEMPLATES: PLANS TO WIND DOWN PHASE 1 CLINICAL STUDIES FOR MT-6402 AND MT-8421   * MOLECULAR TEMPLATES: TO CONTINUE DISCUSSIONS WITH FDA WITH RESPECT TO MT-0169 FOR AUTOIMMUNE INDICATIONS   * MOLECULAR TEMPLATES INC: APPROVED A REDUCTION IN FORCE OF SUBSTANTIALLY ALL OF COMPANY'S EMPLOYEESSource text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MTEM":"Molecular Templates, Inc."},"translate_title":"简介-分子模板批准清算并通过解散结束","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTEM":0.9},"content_text":"Molecular Templates Inc   :   * MOLECULAR TEMPLATES: APPROVED LIQUIDATION & WIND UP THROUGH A DISSOLUTION   * MOLECULAR TEMPLATES: CONTINUING TO PURSUE STRATEGIC ALTERNATIVES AND POTENTIAL FUNDING SOURCES   * MOLECULAR TEMPLATES: INTENDS TO CALL SPECIAL MEETING OF STOCKHOLDERS TO SEEK APPROVAL OF PLAN OF DISTRIBUTION   * MOLECULAR TEMPLATES: PLANS TO WIND DOWN PHASE 1 CLINICAL STUDIES FOR MT-6402 AND MT-8421   * MOLECULAR TEMPLATES: TO CONTINUE DISCUSSIONS WITH FDA WITH RESPECT TO MT-0169 FOR AUTOIMMUNE INDICATIONS   * MOLECULAR TEMPLATES INC: APPROVED A REDUCTION IN FORCE OF SUBSTANTIALLY ALL OF COMPANY'S EMPLOYEESSource text for Eikon:    Further company coverage:","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}